news
NICE recommends Xofigo (radium-223) for prostate cancer
19 November 2015 | By Victoria White
NICE’s FAD coincides with a period of great uncertainty with the Cancer Drugs Fund deliberating again whether to remove radium-223 from the list...
List view / Grid view
National Institute for Health and Care Excellence (NICE)
news
NICE says ‘no’ to Amgen’s Repatha in draft guidance
18 November 2015 | By Victoria White
The NICE Committee felt the question whether Repatha (evolocumab) would reduce angina, heart attacks and strokes remains unanswered...
news
Kadcyla ‘price remains too high’, says NICE
17 November 2015 | By Victoria White
NICE has published final draft guidance not recommending the use of Kadcyla as a treatment for a type of advanced breast cancer because the price is too high...
news
NICE recommends Ikervis in final draft guidance
4 November 2015 | By Victoria White
Ikervis has been recommended for the treatment of keratitis in adults with dry eye disease who have not responded to tear substitutes...
news
NICE recommends tolvaptan for patients with ADPKD
28 October 2015 | By Victoria White
Tolavptan is the first-ever treatment shown to slow progression of the life-threatening condition...
news
NICE recommends ezetimibe for hypercholesterolaemia
21 October 2015 | By Victoria White
The new draft guidance is different to the original 2007 guidance because it reflects the fact that current clinical practice has a greater emphasis on managing CVD risk rather than meeting target cholesterol levels...
news
NICE issues positive guidance for Viekirax + Exviera in HCV
19 October 2015 | By Victoria White
Viekirax and Exviera are the first treatments for chronic HCV to combine three direct-acting antiviral agents to target the infection at multiple steps in the viral lifecycle...
